158 related articles for article (PubMed ID: 19851471)
1. A systematic review of new advances in the management of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): focus on galsulfase.
El Dib RP; Pastores GM
Biologics; 2009; 3():459-68. PubMed ID: 19851471
[TBL] [Abstract][Full Text] [Related]
2. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI.
Brunelli MJ; Atallah ÁN; da Silva EM
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD009806. PubMed ID: 34533215
[TBL] [Abstract][Full Text] [Related]
3. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI.
Brunelli MJ; Atallah ÁN; da Silva EM
Cochrane Database Syst Rev; 2016 Mar; 3():CD009806. PubMed ID: 26943923
[TBL] [Abstract][Full Text] [Related]
4. Galsulfase: arylsulfatase B, BM 102, recombinant human arylsulfatase B, recombinant human N-acetylgalactosamine-4-sulfatase, rhASB.
Drugs R D; 2005; 6(5):312-5. PubMed ID: 16128602
[TBL] [Abstract][Full Text] [Related]
5. The effect of galsulfase enzyme replacement therapy on the growth of patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).
Harmatz P; Hendriksz CJ; Lampe C; McGill JJ; Parini R; Leão-Teles E; Valayannopoulos V; Cole TJ; Matousek R; Graham S; Guffon N; Quartel A;
Mol Genet Metab; 2017 Sep; 122(1-2):107-112. PubMed ID: 28457718
[TBL] [Abstract][Full Text] [Related]
6. Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase.
Brands MM; Hoogeveen-Westerveld M; Kroos MA; Nobel W; Ruijter GJ; Özkan L; Plug I; Grinberg D; Vilageliu L; Halley DJ; van der Ploeg AT; Reuser AJ
Orphanet J Rare Dis; 2013 Apr; 8():51. PubMed ID: 23557332
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics, pharmacokinetics and biodistribution of recombinant human N-acetylgalactosamine 4-sulfatase after 6months of therapy in cats using different IV infusion durations.
Ruane T; Haskins M; Cheng A; Wang P; Aguirre G; Knox VW; Qi Y; Tompkins T; O'Neill CA
Mol Genet Metab; 2016 Feb; 117(2):157-63. PubMed ID: 26776148
[TBL] [Abstract][Full Text] [Related]
8. Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)--10-year follow-up of patients who previously participated in an MPS VI Survey Study.
Giugliani R; Lampe C; Guffon N; Ketteridge D; Leão-Teles E; Wraith JE; Jones SA; Piscia-Nichols C; Lin P; Quartel A; Harmatz P
Am J Med Genet A; 2014 Aug; 164A(8):1953-64. PubMed ID: 24764221
[TBL] [Abstract][Full Text] [Related]
9. Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance.
Akyol MU; Alden TD; Amartino H; Ashworth J; Belani K; Berger KI; Borgo A; Braunlin E; Eto Y; Gold JI; Jester A; Jones SA; Karsli C; Mackenzie W; Marinho DR; McFadyen A; McGill J; Mitchell JJ; Muenzer J; Okuyama T; Orchard PJ; Stevens B; Thomas S; Walker R; Wynn R; Giugliani R; Harmatz P; Hendriksz C; Scarpa M; ;
Orphanet J Rare Dis; 2019 May; 14(1):118. PubMed ID: 31142378
[TBL] [Abstract][Full Text] [Related]
10. Fifteen years of enzyme replacement therapy for mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): a case report.
Andrade I; Ribeiro R; Carneiro ZA; Giugliani R; Pereira C; Cozma C; Grinberg D; Vilageliu L; Lourenco CM
J Med Case Rep; 2022 Jan; 16(1):46. PubMed ID: 35078524
[TBL] [Abstract][Full Text] [Related]
11. Reversed papilledema in an MPS VI patient with galsulfase (Naglazyme) therapy.
Koseoglu ST; Harmatz P; Turbeville S; Nicely H
Int Ophthalmol; 2009 Aug; 29(4):267-9. PubMed ID: 18418554
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes of patients with mucopolysaccharidosis VI treated with galsulfase enzyme replacement therapy since infancy.
Garcia P; Phillips D; Johnson J; Martin K; Randolph LM; Rosenfeld H; Harmatz P
Mol Genet Metab; 2021 May; 133(1):100-108. PubMed ID: 33775523
[TBL] [Abstract][Full Text] [Related]
13. Enzyme replacement therapy initiated in adulthood: Findings from the mucopolysaccharidosis VI Clinical Surveillance Program.
Lampe C; Harmatz PR; Parini R; Sharma R; Teles EL; Johnson J; Sivam D; Sisic Z
Mol Genet Metab; 2019 Aug; 127(4):355-360. PubMed ID: 31324526
[TBL] [Abstract][Full Text] [Related]
14. Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI): a single dose of galsulfase further reduces urine glycosaminoglycans after hematopoietic stem cell transplantation.
Whitley CB; Utz JR
Mol Genet Metab; 2010 Dec; 101(4):346-8. PubMed ID: 20800524
[TBL] [Abstract][Full Text] [Related]
15. Thrombocytopenia associated with galsulfase treatment.
Doğan M; Cesur Y; Peker E; Oner AF; Dogan SZ
Hum Exp Toxicol; 2011 Jul; 30(7):768-71. PubMed ID: 20670992
[TBL] [Abstract][Full Text] [Related]
16. Enzyme replacement therapy outcomes across the disease spectrum: Findings from the mucopolysaccharidosis VI Clinical Surveillance Program.
Harmatz PR; Lampe C; Parini R; Sharma R; Teles EL; Johnson J; Sivam D; Sisic Z
J Inherit Metab Dis; 2019 May; 42(3):519-526. PubMed ID: 30834539
[TBL] [Abstract][Full Text] [Related]
17. Long-term impact of early initiation of enzyme replacement therapy in 34 MPS VI patients: A resurvey study.
Horovitz DDG; Leão EKEA; Ribeiro EM; Martins AM; Barth AL; Neri JICF; Kerstenetzky M; Siqueira ACM; Ribeiro BFR; Kim CA; Santos FC; Franco JFS; Lichtvan LCL; Giuliani LR; Rodrigues MDCS; Bonatti RCF; Teixeira TB; Gonçalves A; Lourenço CM; Pereira ASS; Acosta AX
Mol Genet Metab; 2021 May; 133(1):94-99. PubMed ID: 33678523
[TBL] [Abstract][Full Text] [Related]
18. Clinical Evolution After Enzyme Replacement Therapy in Twins with the Severe Form of Maroteaux-Lamy Syndrome.
Pineda M; O'Callaghan M; Fernandez Lopez A; Coll MJ; Ullot R; Garcia-Fructuoso G
JIMD Rep; 2016; 30():7-14. PubMed ID: 26920906
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of endurance measures for evaluation of treatment in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).
McDonald A; Steiner R; Kuehl K; Turbeville S
J Pediatr Rehabil Med; 2010; 3(2):119-27. PubMed ID: 21791839
[TBL] [Abstract][Full Text] [Related]
20. Enzyme replacement therapy with galsulfase in 34 children younger than five years of age with MPS VI.
Horovitz DD; Magalhães TS; Acosta A; Ribeiro EM; Giuliani LR; Palhares DB; Kim CA; de Paula AC; Kerstenestzy M; Pianovski MA; Costa MI; Santos FC; Martins AM; Aranda CS; Correa Neto J; Holanda GB; Cardoso L; da Silva CA; Bonatti RC; Ribeiro BF; Rodrigues Mdo C; Llerena JC
Mol Genet Metab; 2013 May; 109(1):62-9. PubMed ID: 23535281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
